The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | Efficacy of CD45RA- T-cell infusion to treat infections in immunocompromised patients and EBV-LPDs
Antonio Perez-Martinez, MD, PhD, La Paz University Hospital, Madrid, Spain, discusses the use of CD45RA- cells containing cytotoxic T lymphocytes (CTLs) to treat severe refractory infections and EBV lymphoproliferative diseases (LPDs) immunocompromised patients. The poster, which was presented by Dr Perez-Martinez at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France, demonstrates a feasible adoptive cell therapy that could be a safe and effective approach for treating severe infections.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
